<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Drotrecogin alfa</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Drotrecogin_alfa">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Drotrecogin alfa</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Drotrecogin alfa (activated)</b> (<b>Xigris</b>, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized.<span class="mw-ref" id="cite_ref-1"><a href="#cite_note-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span>  On October 25, 2011, Eli Lilly &amp; Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis.<span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Drotrecogin alfa</span></caption><tbody><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/drotrecogin-alfa-activated.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/drotrecogin-alfa-activated.html'" tppabs="https://www.drugs.com/monograph/drotrecogin-alfa-activated.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">

<ul><li>C</li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>i.v. application only</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>B01AD10<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=B01AD10  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=B01AD10'" tppabs="https://www.whocc.no/atc_ddd_index/?code=B01AD10" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li>Rx-only, not a controlled substance</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>100% (i.v. application only)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>endogenous plasma protease inhibitors</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>less than 2 hours</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">Activated human protein C</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=98530-76-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=98530-76-8'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=98530-76-8" class="external text external">98530-76-8</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6788  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6788'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6788" class="external text external">6788</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00055  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00055'" tppabs="https://www.drugbank.ca/drugs/DB00055" class="external text external">DB00055</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=JGH8MYC891  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=JGH8MYC891'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=JGH8MYC891" class="external text external">JGH8MYC891</a></span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>1786</sub><span>H</span><sub>2779</sub><span>N</span><sub>509</sub><span>O</span><sub>519</sub><span>S</span><sub>29</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">40<span style="margin-left:.25em;">615</span>.66</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=457450996&page2=Drotrecogin+alfa  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=457450996&page2=Drotrecogin+alfa'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=457450996&page2=Drotrecogin+alfa" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Drotrecogin alfa does not improve mortality in severe sepsis or septic shock but does increase bleeding risks. Therefore, a 2012 Cochrane review recommended that clinicians and policymakers not recommend its use and Eli Lilly has announced the discontinuation of all clinical trials.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Risks_and_contraindications">Risks and contraindications</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Contraindications">Contraindications</h3></summary>
    
<p>The following patients should not receive drotrecogin:</p>
<ul><li>Active internal bleeding</li>
<li>Recent (within 3 months) hemorrhagic stroke</li>
<li>Recent (within 2 months) intracranial/intraspinal surgery/severe head trauma</li>
<li>Trauma patients with an increased risk of life-threatening bleeding</li>
<li>Presence of an epidural catheter</li>
<li>Known or suspected intracranial neoplasm or mass lesion</li>
<li>Known hypersensitivity to drotrecogin or any component</li></ul>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Precautions">Precautions</h3></summary>
    
<p>The following patients are at an increased risk for bleeding complications due to drotrecogin-alpha therapy, and a careful risk/benefit assessment should be made prior to initiating therapy.</p>
<ul><li>Therapeutic Heparin (&gt;15 units/kg/h)</li>
<li>Platelet count &lt;30,000/mm3</li>
<li>Recent (within 6 weeks) gastrointestinal bleeding</li>
<li>Recent administration (within 3 days) of thrombolytic therapy</li>
<li>Recent administration (within 7 days) of oral anticoagulants or GP IIb/IIIa inhibitors</li>
<li>Recent administration (within 7 days) of &gt;650<span>&nbsp;</span>mg/day of aspirin or other platelet inhibitors</li>
<li>Recent (within 3 months) ischemic stroke</li>
<li>Known or suspected intracranial AV malformation or aneurysm</li>
<li>Known bleeding diathesis (e.g., hemophilia) except for acute coagulopathy related to sepsis</li>
<li>Chronic severe hepatic disease</li>
<li>HIV infection in association with a last known CD4 count of &lt;50/mm3</li>
<li>Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location</li>
<li>Because drotrecogin-alpha is a therapeutic protein, there exists a potential for immunogenicity. Antibodies against drotrecogin have been observed. There is insufficient data at this time to quantify the risk, but extreme caution should be exercised if a patient has previously received drotrecogin-alpha.</li></ul>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Side-effects">Side-effects</h3></summary>
    
<p>Although patients at high risk of bleeding were excluded from the phase III clinical study (PROWESS), 25% of patients treated with drotrecogin and 18% of those receiving placebo experienced at least one bleeding event (principally ecchymoses or GI bleeding) during the 28-day study period. During treatment serious bleeding events (e.g., intracranial hemorrhage, any life-threatening bleeding event, any bleeding event requiring administration of at least 3 units of packed red blood cells daily for 2 consecutive days) occurred in 2.4% of patients treated with drotrecogin and in 1% of those receiving placebo. No significant differences between geriatric patients and younger patients regarding bleeding events in the drotrecogin group have been found.</p>

<p>No other side-effects have been observed so far.</p>

<p>In the meantime a second study encompassing approximately 2,000 adult patients has been completed and the results showed a comparable side-effect profile.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Interactions">Interactions</h3></summary>
    
<p>Drug interactions with drotrecogin have not been systematically studied in patients with severe sepsis. Caution should be exercised when using other drugs that affect hemostasis concomitantly with drotrecogin (e.g. <a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">aspirin</a>, <a href="Warfarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Warfarin" title="Warfarin">warfarin</a>, <a href="Clopidogrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Clopidogrel" title="Clopidogrel">clopidogrel</a>). However, the use of low dose prophylactic Heparin did not affect safety when given concurrently with drotrecogin.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mechanism_of_action">Mechanism of action</h3></summary>
    
<p>The specific mechanisms by which drotrecogin exerts its effect on survival in patients with severe sepsis is not completely understood. In vitro data suggest that activated protein C exerts an antithrombotic effect by inhibiting factors Va and VIIIa, and that it has indirect profibrinolytic activity by inhibiting plasminogen activator inhibitor-1 (PAI-1). In vitro data also suggest that activated protein C may exert an anti-inflammatory effect by inhibiting <a href="Tumor_necrosis_factors.htm" tppabs="https://ptable.com/wiki/compounds/A/Tumor_necrosis_factors" title="Tumor necrosis factors" class="mw-redirect">tumor necrosis factor</a> production, by blocking leukocyte adhesion to selectins, and by limiting the thrombin-induced inflammatory responses within the microvascular endothelium.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>If the dosage guidelines are followed, the drug reaches peak plasma levels after two hours and is completely cleared from plasma two hours after termination of the infusion period. Endogenous plasma protease inhibitors deactivate drotrecogin. Therefore, no dose adjustment is needed in elderly patients, or in patients with renal or hepatic dysfunction.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Presentation">Presentation</h3></summary>
    
<p>Xigris is the current brand name of activated drotrecogin alfa, manufactured by Eli Lilly. The drug is sold in vials containing either 5<span>&nbsp;</span>mg or 20<span>&nbsp;</span>mg, respectively. The United States' Food and Drug Administration (FDA) approved the drug in 2001 as was the case with the drug authorities in many other countries.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Marketing_controversy">Marketing controversy</h3></summary>
    

<p>In 2001, Eli Lilly's chairman, president and CEO, Sidney Taurel, told shareholders: "No medicine better symbolizes our mission than Xigris," calling it "one of our industry's genuine breakthroughs."<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>

<p>Xigris was designed to fight sepsis, a condition that kills more than 200,000 Americans annually. It was the only approved drug for sepsis, and it costs $8,000 to treat a single patient. Lilly hoped it would be a blockbuster, with sales of at least a billion dollars a year. But after five years on the market, sales were only $200 million.</p>

<p>Eli Lilly used the Belsito &amp; Company PR firm in a marketing campaign to promote Xigris, its drug for treatment of sepsis. A report in the New England Journal of Medicine (NEJM) accused the company of initiating false reports of a shortage of the drug to boost sales.<span class="mw-ref" id="cite_ref-pmid17050887_6-0"><a href="#cite_note-pmid17050887-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Belsito and Company spread the word that the drug was being "rationed" and physicians were being 'systematically forced' to decide who would live and who would die. As part of this effort, Lilly provided a group of physicians and bioethicists with a $1.8 million grant to form the Values, Ethics, and Rationing in Critical Care (VERICC) Task Force, purportedly to address ethical issues raised by rationing in the intensive care unit. Finally, the Surviving Sepsis Campaign was established, in theory to raise awareness of severe sepsis and generate momentum toward the development of treatment guidelines.</p>

<p>This marketing campaign was especially troublesome because Xigris has been linked to increased risk of serious bleeding in patients who used it as well as other concerns. "Controversy surrounds both the drug study itself and the FDA approval," wrote NEJM editor-at-large Richard P. Wenzel, MD in 2002.<span class="mw-ref" id="cite_ref-urlMedscape.com_Log_In_7-0"><a href="#cite_note-urlMedscape.com_Log_In-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span>  The FDA approved the drug despite the advisory committee's split vote (10 to 10) due to concerns about the validity of the claimed efficacy and safety findings on the basis of a single trial.</p>

<p>Eli Lilly spokeswoman Judy Kay Moore insisted that the company did not mastermind the ethics task force or steer the guideline-writing process. It was only a coincidence, Moore says, that the ethics task force and the Surviving Sepsis Campaign used the same P.R. firm, Belsito and Company.<span class="mw-ref" id="cite_ref-urlReport:_Lilly_Promoted_Drug_Under_False_Pretenses_:_NPR_8-0"><a href="#cite_note-urlReport:_Lilly_Promoted_Drug_Under_False_Pretenses_:_NPR-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="FDA_approval">FDA approval</h3></summary>
    
<p>In the USA drotrecogin was FDA approved for the reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death (as determined by APACHE II scores of 25 or greater).  Evidence however is not sufficiently strong for its use to become standard of care.<span class="mw-ref" id="cite_ref-pmid12324562_9-0"><a href="#cite_note-pmid12324562-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>

<p>Because of the risk of severe bleeding, associated with the use of Xigris, the following guidelines have been additionally proposed, but are not FDA requirements:</p>
<ul><li>Drotrecogin should only be ordered by a critical care specialist with experience weighing the risks and benefits of this medication.</li>
<li>Drotrecogin should only be administered in a critical care area such as an Intensive Care Unit (ICU), or other unit with very frequent observation and monitoring.</li></ul>

<p>On October 25, 2011, Eli Lilly and Company announced a worldwide voluntary market withdrawal of Xigris [drotrecogin alfa (activated)]. In a recent study, Xigris failed to show a survival benefit for patients with severe sepsis and septic shock.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>The exact mechanism for this protein is currently not known, but efforts continue to isolate activated protein C mutants that lack anticoagulant properties for potential therapeutic use.<span class="mw-ref" id="cite_ref-Angus_2013_11-0"><a href="#cite_note-Angus_2013-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="mw-references references"><li id="cite_note-1"> <span id="mw-reference-text-cite_note-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://blogs.scientificamerican.com/guest-blog/2011/11/02/lillys-shocker-or-the-post-marketing-blues  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://blogs.scientificamerican.com/guest-blog/2011/11/02/lillys-shocker-or-the-post-marketing-blues'" tppabs="http://blogs.scientificamerican.com/guest-blog/2011/11/02/lillys-shocker-or-the-post-marketing-blues" class="external text external">"Lilly's Shocker, or the Post-Marketing Blues"</a>. <i>guest blog</i>. Scientific American.</cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20111028112048/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2011%2F10%2Fnews_detail_001373.jsp&mid=WC0b01ac058004d5c1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20111028112048/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2011%2F10%2Fnews_detail_001373.jsp&mid=WC0b01ac058004d5c1'" tppabs="https://web.archive.org/web/20111028112048/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2011%2F10%2Fnews_detail_001373.jsp&mid=WC0b01ac058004d5c1" class="external text external">"Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy"</a>. <i>Press release</i>. London, UK: European Medicines Agency. 25 October 2011. Archived from <a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2011%2F10%2Fnews_detail_001373.jsp&mid=WC0b01ac058004d5c1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2011%2F10%2Fnews_detail_001373.jsp&mid=WC0b01ac058004d5c1'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2011%2F10%2Fnews_detail_001373.jsp&mid=WC0b01ac058004d5c1" class="external text external">the original</a> on 28 October 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">26 October</span> 2011</span>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite id="CITEREFArmstrong2011" class="citation news cs1">Armstrong, Drew (October 25, 2011). <a href="javascript:if(confirm('https://web.archive.org/web/20111029155823/http://www.businessweek.com/news/2011-10-25/lilly-pulls-xigris-off-markets-after-sepsis-drug-fails-study.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20111029155823/http://www.businessweek.com/news/2011-10-25/lilly-pulls-xigris-off-markets-after-sepsis-drug-fails-study.html'" tppabs="https://web.archive.org/web/20111029155823/http://www.businessweek.com/news/2011-10-25/lilly-pulls-xigris-off-markets-after-sepsis-drug-fails-study.html" class="external text external">"Lilly Pulls Xigris Off Markets After Sepsis Drug Fails Study"</a>. <i>Bloomberg BusinessWeek</i>. Archived from <a href="javascript:if(confirm('http://www.businessweek.com/news/2011-10-25/lilly-pulls-xigris-off-markets-after-sepsis-drug-fails-study.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.businessweek.com/news/2011-10-25/lilly-pulls-xigris-off-markets-after-sepsis-drug-fails-study.html'" tppabs="http://www.businessweek.com/news/2011-10-25/lilly-pulls-xigris-off-markets-after-sepsis-drug-fails-study.html" class="external text external">the original</a> on October 29, 2011.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite id="CITEREFMartí-CarvajalSolàGluudLathyris2012" class="citation journal cs1">Martí-Carvajal, Arturo J.; Solà, Ivan; Gluud, Christian; Lathyris, Dimitrios; Cardona, Andrés Felipe (2012-12-12). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464614  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464614'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464614" class="external text external">"Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>12</b>: CD004388. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD004388.pub6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD004388.pub6'" tppabs="https://doi.org/10.1002%2F14651858.CD004388.pub6" class="external text external">10.1002/14651858.CD004388.pub6</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1469-493X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1469-493X'" tppabs="https://www.worldcat.org/issn/1469-493X" class="external text external">1469-493X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464614  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464614'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464614" class="external text external">6464614</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23235609  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23235609'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23235609" class="external text external">23235609</a>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20070226063136/http://lilly.com/investor/annual_report/lillyar2001editorial.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070226063136/http://lilly.com/investor/annual_report/lillyar2001editorial.pdf'" tppabs="https://web.archive.org/web/20070226063136/http://lilly.com/investor/annual_report/lillyar2001editorial.pdf" class="external text external">"Eli Lilly Annual Report, 2001"</a> <span class="cs1-format">(PDF)</span>. Archived from <a href="javascript:if(confirm('http://lilly.com/investor/annual_report/lillyar2001editorial.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://lilly.com/investor/annual_report/lillyar2001editorial.pdf'" tppabs="http://lilly.com/investor/annual_report/lillyar2001editorial.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2007-02-26<span class="reference-accessdate">. Retrieved <span class="nowrap">2008-08-17</span></span>.</cite></span></li><li id="cite_note-pmid17050887-6"> <span id="mw-reference-text-cite_note-pmid17050887-6" class="mw-reference-text"><cite id="CITEREFEichackerNatansonDanner2006" class="citation journal cs1">Eichacker PQ, Natanson C, Danner RL (October 2006). "Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly". <i>N. Engl. J. Med</i>. <b>355</b> (16): 1640–2. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMp068197  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMp068197'" tppabs="https://doi.org/10.1056%2FNEJMp068197" class="external text external">10.1056/NEJMp068197</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17050887  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17050887'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17050887" class="external text external">17050887</a>.</cite></span></li><li id="cite_note-urlMedscape.com_Log_In-7"> <span id="mw-reference-text-cite_note-urlMedscape.com_Log_In-7" class="mw-reference-text"><cite id="CITEREFBarclay_L2002" class="citation web cs1">Barclay L (2002-10-01). <a href="javascript:if(confirm('https://web.archive.org/web/20021015023647/http://www.medscape.com/viewarticle/442255  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20021015023647/http://www.medscape.com/viewarticle/442255'" tppabs="https://web.archive.org/web/20021015023647/http://www.medscape.com/viewarticle/442255" class="external text external">"Controversy Brews Over Xigris' Role in Treating Sepsis"</a>. <i>Medscape Medical News</i>. WebMD LLC. Archived from <a href="javascript:if(confirm('http://www.medscape.com/viewarticle/442255  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medscape.com/viewarticle/442255'" tppabs="http://www.medscape.com/viewarticle/442255" class="external text external">the original</a> on 2002-10-15<span class="reference-accessdate">. Retrieved <span class="nowrap">2010-09-19</span></span>.</cite></span></li><li id="cite_note-urlReport:_Lilly_Promoted_Drug_Under_False_Pretenses_:_NPR-8"> <span id="mw-reference-text-cite_note-urlReport:_Lilly_Promoted_Drug_Under_False_Pretenses_:_NPR-8" class="mw-reference-text"><cite id="CITEREFKnox_R2006" class="citation web cs1">Knox R (2006-10-18). <a href="javascript:if(confirm('https://web.archive.org/web/20061019001123/http://www.npr.org/templates/story/story.php?storyId=6298643  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20061019001123/http://www.npr.org/templates/story/story.php?storyId=6298643'" tppabs="https://web.archive.org/web/20061019001123/http://www.npr.org/templates/story/story.php?storyId=6298643" class="external text external">"Report: Lilly Promoted Drug Under False Pretenses"</a>. <i>All Things Considered</i>. National Public Radio. Archived from <a href="javascript:if(confirm('https://www.npr.org/templates/story/story.php?storyId=6298643  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.npr.org/templates/story/story.php?storyId=6298643'" tppabs="https://www.npr.org/templates/story/story.php?storyId=6298643" class="external text external">the original</a> on 2006-10-19<span class="reference-accessdate">. Retrieved <span class="nowrap">2010-09-19</span></span>.</cite></span></li><li id="cite_note-pmid12324562-9"> <span id="mw-reference-text-cite_note-pmid12324562-9" class="mw-reference-text"><cite id="CITEREFWarrenSuffrediniEichackerMunford2002" class="citation journal cs1">Warren HS, Suffredini AF, Eichacker PQ, Munford RS (September 2002). "Risks and benefits of activated protein C treatment for severe sepsis". <i>N. Engl. J. Med</i>. <b>347</b> (13): 1027–30. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMsb020574  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMsb020574'" tppabs="https://doi.org/10.1056%2FNEJMsb020574" class="external text external">10.1056/NEJMsb020574</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12324562  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12324562'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12324562" class="external text external">12324562</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/Drugs/DrugSafety/ucm277114.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/DrugSafety/ucm277114.htm'" tppabs="https://www.fda.gov/Drugs/DrugSafety/ucm277114.htm" class="external text external">"FDA Drug Safety Communication: Voluntary market withdrawal of Xigris <span>[</span>drotrecogin alfa (activated)<span>]</span> due to failure to show a survival benefit"</a>. <i>fda.gov</i>. U.S. Department of Health and Human Services. October 25, 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">May 24,</span> 2017</span>.</cite></span></li><li id="cite_note-Angus_2013-11"> <span id="mw-reference-text-cite_note-Angus_2013-11" class="mw-reference-text"><cite id="CITEREFAngusvan_der_Poll2013" class="citation journal cs1">Angus, Derek C.; van der Poll, Tom (29 August 2013). "Severe Sepsis and Septic Shock". <i>New England Journal of Medicine</i>. <b>369</b> (9): 840–851. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMra1208623  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMra1208623'" tppabs="https://doi.org/10.1056%2FNEJMra1208623" class="external text external">10.1056/NEJMra1208623</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23984731  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23984731'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23984731" class="external text external">23984731</a>.</cite></span></li></ol></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><span class="official-website"><span class="url"><a href="javascript:if(confirm('http://www.xigris.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.xigris.com/'" tppabs="http://www.xigris.com/" class="external text external">Official website</a></span></span></li>
<li><a href="javascript:if(confirm('https://www.fda.gov/medwatch/SAFETY/2005/xigris_USPI_17Dec04.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/medwatch/SAFETY/2005/xigris_USPI_17Dec04.pdf'" tppabs="https://www.fda.gov/medwatch/SAFETY/2005/xigris_USPI_17Dec04.pdf" class="external text external">Information</a> (PDF) on the drug from the Food and Drug Administration (FDA).</li></ul>

<div role="navigation" class="navbox" aria-labelledby="Antithrombotics_(thrombolytics,_anticoagulants_and_antiplatelet_drugs)_(B01)" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Antithrombotics_(thrombolytics,_anticoagulants_and_antiplatelet_drugs)_(B01)" style="font-size:114%;margin:0 4em">Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antiplatelet drugs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Glycoprotein IIb/IIIa inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Abciximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Abciximab" title="Abciximab">Abciximab</a></li>
<li><a href="Eptifibatide.htm" tppabs="https://ptable.com/wiki/compounds/A/Eptifibatide" title="Eptifibatide">Eptifibatide</a></li>
<li><span class="new">Orbofiban</span></li>
<li><span class="new">Roxifiban</span></li>
<li>Sibrafiban<sup>§</sup></li>
<li><a href="Tirofiban.htm" tppabs="https://ptable.com/wiki/compounds/A/Tirofiban" title="Tirofiban">Tirofiban</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">ADP receptor/P2Y<sub>12</sub> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Thienopyridines
<ul><li><a href="Clopidogrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Clopidogrel" title="Clopidogrel">Clopidogrel</a></li>
<li>Prasugrel</li>
<li><a href="Ticlopidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ticlopidine" title="Ticlopidine">Ticlopidine</a></li></ul></li>
<li>Nucleotide/nucleoside analogs
<ul><li>Cangrelor</li>
<li>Elinogrel</li>
<li>Ticagrelor</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Prostaglandin analogue (<a href="Prostacyclin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostacyclin" title="Prostacyclin">PGI2</a>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Beraprost</li>
<li><a href="Iloprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Iloprost" title="Iloprost">Iloprost</a></li>
<li><a href="Prostacyclin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostacyclin" title="Prostacyclin">Prostacyclin</a></li>
<li><a href="Treprostinil.htm" tppabs="https://ptable.com/wiki/compounds/A/Treprostinil" title="Treprostinil">Treprostinil</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">COX inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Acetylsalicylic acid/Aspirin</a><sup>#</sup></li>
<li>Aloxiprin</li>
<li>Carbasalate calcium</li>
<li>Indobufen</li>
<li>Triflusal</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Thromboxane inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Thromboxane synthase inhibitors
<ul><li><a href="Dipyridamole.htm" tppabs="https://ptable.com/wiki/compounds/A/Dipyridamole" title="Dipyridamole">Dipyridamole</a> (+ aspirin)</li>
<li><a href="Picotamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Picotamide" title="Picotamide">Picotamide</a></li>
<li>Terbogrel</li></ul></li>
<li>Receptor antagonists
<ul><li>Terbogrel</li>
<li>Terutroban<sup>§</sup></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Phosphodiesterase inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Cilostazol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cilostazol" title="Cilostazol">Cilostazol</a></li>
<li><a href="Dipyridamole.htm" tppabs="https://ptable.com/wiki/compounds/A/Dipyridamole" title="Dipyridamole">Dipyridamole</a></li>
<li>Triflusal</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cloricromen</li>
<li>Ditazole</li>
<li>Vorapaxar</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anticoagulants</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Vitamin K antagonists<br>(inhibit <a href="Thrombin.htm" tppabs="https://ptable.com/wiki/compounds/A/Thrombin" title="Thrombin">II</a>, VII, IX, X)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Coumarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumarin" title="Coumarin">Coumarins</a>: <a href="Acenocoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Acenocoumarol" title="Acenocoumarol">Acenocoumarol</a></li>
<li><a href="Coumatetralyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumatetralyl" title="Coumatetralyl">Coumatetralyl</a></li>
<li><a href="Dicoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dicoumarol" title="Dicoumarol">Dicoumarol</a></li>
<li>Ethyl biscoumacetate</li>
<li><a href="Phenprocoumon.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenprocoumon" title="Phenprocoumon">Phenprocoumon</a></li>
<li><a href="Warfarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Warfarin" title="Warfarin">Warfarin</a><sup>#</sup></li>
<li><a href="1,3-Indandione.htm" tppabs="https://ptable.com/wiki/compounds/A/1%2C3-Indandione" title="1,3-Indandione">1,3-Indandiones</a>: Clorindione</li>
<li><a href="Diphenadione.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenadione" title="Diphenadione">Diphenadione</a></li>
<li><a href="Phenindione.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenindione" title="Phenindione">Phenindione</a></li>
<li>Other: Tioclomarol</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Factor Xa inhibitors<br>(with some II inhibition)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Heparin.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparin" title="Heparin">Heparin</a> group/<br>glycosaminoglycans/<br>(bind antithrombin)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Low-molecular-weight heparin
<ul><li>Bemiparin</li>
<li>Certoparin</li>
<li><a href="Dalteparin_sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Dalteparin_sodium" title="Dalteparin sodium">Dalteparin</a></li>
<li><a href="Enoxaparin_sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Enoxaparin_sodium" title="Enoxaparin sodium">Enoxaparin</a></li>
<li>Nadroparin</li>
<li>Parnaparin</li>
<li>Reviparin</li>
<li>Tinzaparin</li></ul></li>
<li>Oligosaccharides
<ul><li><a href="Fondaparinux.htm" tppabs="https://ptable.com/wiki/compounds/A/Fondaparinux" title="Fondaparinux">Fondaparinux</a></li>
<li>Idraparinux<sup>§</sup></li></ul></li>
<li>Heparinoids
<ul><li>Danaparoid</li>
<li><a href="Dermatan_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dermatan_sulfate" title="Dermatan sulfate">Dermatan sulfate</a></li>
<li>Sulodexide</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Direct Xa inhibitors ("xabans")</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Apixaban</li>
<li>Betrixaban</li>
<li>Darexaban<sup>§</sup></li>
<li>Edoxaban</li>
<li>Otamixaban<sup>§</sup></li>
<li>Rivaroxaban</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Direct thrombin (IIa) inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Bivalent: Hirudin
<ul><li><a href="Bivalirudin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bivalirudin" title="Bivalirudin">Bivalirudin</a></li>
<li>Desirudin</li>
<li><a href="Lepirudin.htm" tppabs="https://ptable.com/wiki/compounds/A/Lepirudin" title="Lepirudin">Lepirudin</a></li></ul></li>
<li>Univalent: <a href="Argatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Argatroban" title="Argatroban">Argatroban</a></li>
<li>Dabigatran</li>
<li><span class="new">Efegatran</span></li>
<li>Inogatran<sup>§</sup></li>
<li><a href="Ximelagatran.htm" tppabs="https://ptable.com/wiki/compounds/A/Melagatran" title="Melagatran" class="mw-redirect">Melagatran</a><sup>‡</sup></li>
<li><a href="Ximelagatran.htm" tppabs="https://ptable.com/wiki/compounds/A/Ximelagatran" title="Ximelagatran">Ximelagatran</a><sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antithrombin III</li>
<li>Defibrotide</li>
<li>Protein C
<ul><li><a href="Drotrecogin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Drotrecogin_alfa" title="Drotrecogin alfa">Drotrecogin alfa</a><sup>‡</sup></li></ul></li>
<li><a href="Ramatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Ramatroban" title="Ramatroban">Ramatroban</a></li>
<li>REG1</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Thrombolytic drugs/<br>fibrinolytics</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Plasminogen activators: r-tPA
<ul><li>Alteplase</li>
<li><a href="Reteplase.htm" tppabs="https://ptable.com/wiki/compounds/A/Reteplase" title="Reteplase">Reteplase</a></li>
<li><a href="Tenecteplase.htm" tppabs="https://ptable.com/wiki/compounds/A/Tenecteplase" title="Tenecteplase">Tenecteplase</a></li>
<li>Desmoteplase<sup>†</sup></li></ul></li>
<li>UPA
<ul><li>Saruplase</li>
<li><a href="Urokinase.htm" tppabs="https://ptable.com/wiki/compounds/A/Urokinase" title="Urokinase">Urokinase</a></li></ul></li>
<li><a href="Anistreplase.htm" tppabs="https://ptable.com/wiki/compounds/A/Anistreplase" title="Anistreplase">Anistreplase</a></li>
<li>Monteplase</li>
<li><a href="Streptokinase.htm" tppabs="https://ptable.com/wiki/compounds/A/Streptokinase" title="Streptokinase">Streptokinase</a><sup>#</sup></li>
<li>Other serine endopeptidases: Ancrod</li>
<li>Brinase</li>
<li>Fibrinolysin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-medicinal</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Citrate</li>
<li><a href="Ethylenediaminetetraacetic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylenediaminetetraacetic_acid" title="Ethylenediaminetetraacetic acid">EDTA</a></li>
<li><a href="Oxalate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxalate" title="Oxalate">Oxalate</a></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Intensive_care_medicine" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Intensive_care_medicine" style="font-size:114%;margin:0 4em">Intensive care medicine</div></th></tr><tr><td class="navbox-abovebelow" colspan="2"><div id="*_Health_science_*_Medicine_*_Medical_specialities_*_Respiratory_therapy">
<ul><li>Health science</li>
<li>Medicine</li>
<li>Medical specialities</li>
<li>Respiratory therapy</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">General terms</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Intensive care unit (ICU)</li>
<li>Neonatal intensive care unit (NICU)</li>
<li>Pediatric intensive care unit (PICU)</li>
<li>Coronary care unit (CCU)</li>
<li>Critical illness insurance</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Conditions</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Organ system failure</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<dl><dt>Shock sequence</dt>
<dd>SIRS</dd>
<dd>Sepsis</dd>
<dd>Severe sepsis</dd>
<dd>Septic shock</dd>
<dd>Multiple organ dysfunction syndrome</dd></dl>

<dl><dt>Other shock</dt>
<dd>Cardiogenic shock</dd>
<dd>Distributive shock</dd>
<dd>Anaphylaxis</dd>
<dd>Obstructive shock</dd>
<dd>Neurogenic shock</dd>
<dd>Spinal shock</dd>
<dd>Vasodilatory shock</dd></dl>

<dl><dt>Organ failure</dt>
<dd>Acute renal failure</dd>
<dd>Acute respiratory distress syndrome</dd>
<dd>Acute liver failure</dd>
<dd>Respiratory failure</dd>
<dd>Multiple organ dysfunction syndrome</dd></dl>

<ul><li>Neonatal infection</li>
<li>Polytrauma</li>
<li>Coma</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Complications</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Critical illness polyneuropathy / myopathy</li>
<li>Critical illness–related corticosteroid insufficiency</li>
<li>Decubitus ulcers</li>
<li>Fungemia</li>
<li>Stress hyperglycemia</li>
<li>Stress ulcer</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Iatrogenesis</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Methicillin-resistant <i>Staphylococcus aureus</i></li>
<li>Oxygen toxicity</li>
<li>Refeeding syndrome</li>
<li>Ventilator-associated lung injury</li>
<li>Ventilator-associated pneumonia</li>
<li>Dialytrauma</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Diagnosis</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Arterial blood gas</li>
<li>Catheter
<ul><li>Arterial line</li>
<li>Central venous catheter</li>
<li>Pulmonary artery catheter</li></ul></li>
<li>Blood cultures</li>
<li>Screening cultures</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Life-supporting treatments</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Airway management</li>
<li>Chest tube</li>
<li>Dialysis</li>
<li>Enteral feeding</li>
<li>Goal-directed therapy</li>
<li>Induced coma</li>
<li>Mechanical ventilation</li>
<li>Therapeutic hypothermia</li>
<li>Total parenteral nutrition</li>
<li>Tracheal intubation</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Drugs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Analgesics</li>
<li>Antibiotics</li>
<li>Antithrombotics</li>
<li>Inotropes</li>
<li>Intravenous fluids</li>
<li>Neuromuscular-blocking drugs</li>
<li><a href="Drotrecogin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Drotrecogin_alfa" title="Drotrecogin alfa">Recombinant activated protein<span>&nbsp;</span>C</a></li>
<li>Sedatives</li>
<li>Stress ulcer prevention drugs</li>
<li>Vasopressors</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">ICU scoring systems</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>APACHE&nbsp;II</li>
<li>Glasgow Coma Scale</li>
<li>PIM2</li>
<li>SAPS&nbsp;II</li>
<li>SAPS&nbsp;III</li>
<li>SOFA</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Physiology</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Hemodynamics</li>
<li>Hypotension</li>
<li>Level of consciousness</li>
<li>Acid–base imbalance</li>
<li>Water-electrolyte imbalance</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Organisations</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Society of Critical Care Medicine</li>
<li>Surviving Sepsis Campaign</li>
<li>European Society of Paediatric and Neonatal Intensive Care</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Related specialties</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anesthesiology</li>
<li>Cardiology</li>
<li>Internal medicine</li>
<li>Neurology</li>
<li>Pediatrics</li>
<li>Pulmonology</li>
<li>Surgery</li>
<li>Traumatology</li></ul>
</div></td></tr></tbody></table></div>




<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>